EUPORIA
PEPTIDES

TESAMORELIN

SYNTHETIC GROWTH HORMONE-RELEASING FACTOR ANALOG

WHAT IS TESAMORELIN?



Tesamorelin is a synthetic analog of human growth hormone-releasing factor (GHRF) designed to stimulate the natural release of growth hormone.

IDENTITY

- 44-amino-acid sequence of human growth hormone-releasing factor (GHRF), with a hexenoyl group attached to its N-terminal tyrosine.
- Free-base molecular mass: 5,135.9 Da.
- Prescription EGRIFTA WR contains tesamorelin acetate.

HOW IT WORKS

- Tesamorelin binds and stimulates human GHRF receptors in vitro.
- GHRF signaling in the pituitary promotes pulsatile growth hormone release. Tesamorelin increases GH, IGF-1 and IGFBP-3 levels in clinical pharmacology studies.

CLINICAL EVIDENCE CONTEXT

- Prescription tesamorelin was studied for reducing excess abdominal fat in adults with HIV-associated lipodystrophy.
- It is not indicated for general weight loss. Clinical results for the approved drug do not verify an independently sourced research lot.

LABEL SAFETY CONTEXT

FDA labeling for prescription tesamorelin identifies elevated IGF-1, fluid retention and glucose intolerance among its precautions. These are drug-label findings, not safety testing of this research product.

RESEARCH LOT CHECKS

- Confirm identity and modification
- Quantify content
- Assess purity
- Match results to a lot-specific certificate of analysis

PRIMARY SOURCE

FDA EGRIFTA WR Prescribing Information, revised March 2025: Sections 1, 5, 11, 12 and 14.

KEY POINTS

- Synthetic analog of human GHRF
- Stimulates natural growth hormone release
- Increases GH, IGF-1 and IGFBP-3 levels in clinical pharmacology studies
- Studied for HIV-associated lipodystrophy
- Not indicated for general weight loss
- Safety information is from FDA labeling

FOR LABORATORY RESEARCH ONLY

NOT FOR HUMAN OR VETERINARY USE